-
Mashup Score: 9
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P mean reduction versus placebo of 52.5% at day 180, with small LDL-P reduction of 102.4% – – Safety
Source: ir.newamsterdampharma.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
— Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p0.0001) — — 21% observed reduction in major adverse cardiovascular events favoring obicetrapib at one year – —
Source: ir.newamsterdampharma.comCategories: General Medicine News, CardiologistsTweet-
👉Read more: https://t.co/FER33nTnaO #Cardiology #Lipidology #ASCVD
-
-
Mashup Score: 44
— Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p0.0001), which was sustained at day 365 (p0.0001) — — Obicetrapib lowered LDL-C by 36.3% at day 84 and 41.5% at day 365,
Source: ir.newamsterdampharma.comCategories: General Medicine News, CardiologistsTweet-
🚀 Exciting news from @NewAmsPharma! Their Phase 3 BROOKLYN trial for Obicetrapib in HeFH patients showed remarkable results: LDL-C reduced by 36.3% at 84 days and 41.5% at 365 days! This is a significant milestone in treating HeFH! https://t.co/F8Gdxz09Af
-
-
Mashup Score: 40
— Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p0.0001), which was sustained at day 365 (p0.0001) — — Obicetrapib lowered LDL-C by 36.3% at day 84 and 41.5% at day 365,
Source: ir.newamsterdampharma.comCategories: General Medicine News, CardiologistsTweet-
🚀 Exciting news from @NewAmsPharma! Their Phase 3 BROOKLYN trial for Obicetrapib in HeFH patients showed remarkable results: LDL-C reduced by 36.3% at 84 days and 41.5% at 365 days! This is a significant milestone in treating HeFH! https://t.co/F8Gdxz09Af
-
-
Mashup Score: 3
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p
Source: ir.newamsterdampharma.comCategories: General Medicine News, CardiologistsTweet-
Full Data from Phase 2 ROSE2 Trial Evaluating #Obicetrapib in Combination with #Ezetimibe as an Adjunct to High-Intensity Statin Therapy at #NLA #EAS https://t.co/LXh6uvAPxV
-
@Lpa_Doc this is where new therapies such as obicetrapib, used in combination with statins, may have a massive future role @Lpa_Doc https://t.co/ZZYUp2IUKN @JohnKastelein https://t.co/MRq5LIR0Kd